Vanguard Global Advisers’s MapLight Therapeutics MPLT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$76.8K Sell
7,533
-895
-11% -$16.8K ﹤0.01% 2890
2026
Q2
$302K Hold
8,428
– – ﹤0.01% 2330
2026
Q1
$171K Buy
+8,428
New +$151K ﹤0.01% 2510

Other funds holding MPLT

Vanguard Global Advisers's MPLT Position: Q3 2026 in Review

Vanguard Global Advisers reduced its MapLight Therapeutics (MPLT) stake by 11% in Q3 2026, selling an estimated $16.8K and leaving 7,533 shares worth $76.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2890.

Vanguard Global Advisers first reported a position in MPLT in Q1 2026 and has held it in 3 quarters since. The position peaked at $302K in Q2 2026. 98 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.

  • Vanguard Global Advisers held 7,533 shares of MapLight Therapeutics worth $76.8K as of Q3 2026.
  • Vanguard Global Advisers sold 895 MapLight Therapeutics shares in Q3 2026, an estimated $16.8K.
  • MapLight Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2890 holding.
  • Vanguard Global Advisers first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's MapLight Therapeutics position peaked at $302K in Q2 2026.
  • 98 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.